Moderna and Regeneron: Diverging Paths Ahead of Key Biotech Catalysts
Moderna's price surges ahead of an FDA ruling, while Regeneron faces market challenges despite strong earnings.
Humana's Q2 Performance: A Mixed Bag for Investors in the Pharmaceutical Sector
Humana's Q2 earnings exceeded estimates but left some analysts wanting more, raising questions about the managed care sector's outlook.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Regulatory Changes Impacting Victory Square's Healthcare Ventures
Victory Square Technologies faces new challenges as FDA recommendations could reshape its healthcare portfolio.
United Therapeutics' Ralinepag: A Potential Breakthrough for PAH Treatment
United Therapeutics' ralinepag shows promise in treating pulmonary arterial hypertension, potentially boosting revenue a…
Amgen's MariTide Trials: A Game Changer in the GLP-1 Market?
Amgen's Phase 3 trials for MariTide could disrupt the GLP-1 landscape, intensifying competition with Eli Lilly and Novo …
Strategic Acquisition: Leonardo DRS Expands Defense Capabilities with Raft Purchase
Leonardo DRS enhances its defense portfolio by acquiring Raft, aiming to strengthen its position in AI and data fusion t…
Capricor Therapeutics Faces a Harrowing 65% Drop Amid FDA Concerns: A Cautionary Tale for Investors
Capricor Therapeutics' stock plummets 65% after FDA documents raise concerns about deramiocel, highlighting biotech inve…
Altimmune's Clinical Triumph: What the Phase 2 RECLAIM Data Means for Investors
Altimmune's shares surged 18% following promising Phase 2 data for pemvidutide, signaling a bright future for the compan…
Curium's Potential $7 Billion Acquisition of Lantheus Holdings: What Investors Need to Know
Curium's potential acquisition of Lantheus Holdings could reshape the radiopharmaceutical landscape, but what does this …
Outlook Therapeutics (OTLK) Rises Dramatically Following FDA Approval of Lytenava
OTLK's stock jumps after FDA approval of Lytenava, with analysts projecting nearly 300% upside ahead of its launch.
Capricor Therapeutics (CAPR) Faces Devastating Losses Following FDA Concerns
Capricor Therapeutics suffers a staggering 67% drop as FDA concerns about Deramiocel loom large, dividing analysts on ap…